New combo therapy aims to tame rare blood cancers
NCT ID NCT07071155
First seen Nov 19, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests adding the drug momelotinib to standard treatment for people with certain rare blood cancers (MDS/MPN and chronic neutrophilic leukemia). The goal is to better control the disease, improve symptoms, and help more patients become eligible for a transplant. About 18 adults will take momelotinib pills plus azacitidine injections for up to 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.